Navigation Links
Scientists take aim at virulent bacteria by decoding machinery of key control enzyme

By deciphering the ingenious mechanism used by a particular enzyme to modify bacterial chromosome chemistry, scientists have come a step closer to designing a new kind of drug that could stop virulent bacterial infections in their tracks. Their research will be published in the May 6 issue of the journal Cell.

Scientists have known for many years that an enzyme called Dam (DNA adenine methyltransferase) plays a role in regulating gene expression in many bacteria. Each time the bacteria reproduce, Dam modifies the A (adenine) nucleotide in the DNA sequence GATC through a chemical reaction known as methylation. Methylation is a biological process used to tag a variety of molecules, including DNA, and is important in cellular processes such as regulating gene expression, DNA replication and repair. In humans DNA methylation occurs on the C (cytosine) rather than the A (adenine) nucleotide.

Recently scientists have discovered a new role for Dam methylation. Dam also is essential for regulating the expression of genes responsible for bacterial virulence. When the gene responsible for Dam is defective, bacteria lose their disease-causing potency. Using the X-ray diffraction facility at the Argonne National Laboratory in Chicago, Xiaodong Cheng, PhD, professor of biochemistry at Emory University School of Medicine and Georgia Research Alliance Eminent Scholar, and John Horton, PhD, Research Assistant Professor, have now solved the co-crystal structure of the Dam enzyme in complex with DNA, which has allowed them to observe exactly how the enzyme finds its target on bacterial DNA.

The Dam enzyme begins by binding non-specifically to DNA, but once it fastens tightly, it glides smoothly down the entire DNA molecule like fingers sliding down a guitar neck searching for the right chord, examining each base pair as it goes. Each time it finds the sequence GATC it stops and methylates the A nucleotide. Dam must move quickly, because if the bacteria reproduc e with the wrong methylation pattern, gene expression will be foiled and they will lose their virulence.

"For the first time, using the 3-D crystal structure, we have been able to see the specific Dam structure in action, including the way it binds to the DNA and moves along the base pairs as it recognizes and methylates the A nucleotides," says Dr. Cheng. "Using this information we can potentially design a drug to inhibit this particular enzyme's chemical reaction or its DNA binding process. This kind of rationally designed drug could be an alternative against infections that are resistant to current antibiotics. And because humans don't have Dam methylation, this kind of drug would not interfere with important biological processes in humans."

Other coauthors include Dr. Stanley Hattman, professor of biology from University of Rochester, who cloned and sequenced the Dam gene and has been studying the biochemical mechanism of the enzyme and Dr. Albert Jeltsch and his student Kirsten Liebert from International University Bremen in Germany. Dr. Cheng and his colleagues plan to continue their research using structure-based virtual screening techniques and high throughput equipment to screen for potential inhibitor compounds against the Dam enzyme.


'"/>

Source:Emory University Health Sciences Center


Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/2/2016)... 1, 2016   SoftServe , a global ... , an electrocardiogram (ECG) biosensor analysis system for ... IoT asset. The smart system ensures device-to-device communication ... wheel and mobile devices to easily ,recognize, and ... As vehicle technology advances, so too must the ...
(Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
Breaking Biology Technology: